A Transplant Into Untreated Hair Loss Is a Lawn Planted in a Retreating Garden

The principle that makes transplants work, and the trap inside it

Hair transplantation rests on an observation made in the middle of the last century and known as donor dominance: hair follicles carry their characteristics with them when they are moved. A follicle taken from the back and sides of the scalp — the occipital and temporal donor region — retains whatever made it resistant to androgenetic miniaturisation in its original location. Relocate it to a receding hairline and it keeps growing, indefinitely, as if it were still where it started.

That is genuinely remarkable, and it is why the procedure produces permanent results rather than temporary ones.

Now read the same sentence from the other direction. If a follicle keeps its genetic programme when moved, then the follicles that were already at the front — the ones that were miniaturising because they are susceptible — also keep theirs. Nothing about the surgery changes them. They were on a trajectory before the operation and they remain on it afterwards.

So a transplant into untreated androgenetic alopecia does exactly one thing: it inserts a band of permanent hair into a field that is still, quietly, continuing to recede around and behind it. On the day the grafts mature, the result looks excellent, because the transplanted hair and the native hair are at similar density. The problem is what the two do over the following decade, which is move in opposite directions.

The treadmill, and why donor supply is the thing to protect

Picture the ten-year version, because it is the version nobody is shown at the consultation.

Year one: a restored hairline, a good result, a satisfied patient. Years two to four: the native hair immediately behind the transplanted zone continues miniaturising, because nothing was done about the process driving it. Year five: a visible gap has opened between the dense transplanted band and whatever remains behind it, or the crown — which was never part of the plan — has thinned enough to become the dominant feature. The result now looks worse than it did at year two, and it looks worse in a specific, characteristic way: an isolated strip of density with a see-through zone behind it.

The response is a second procedure to fill the gap. And here is where the arithmetic turns punitive.

Donor supply is finite and non-renewable. You have a fixed number of follicular units in the safe donor zone — an area whose boundaries are themselves an estimate, since how far the loss will eventually extend is not knowable in advance. Every graft harvested is permanently gone from the bank. Harvesting more aggressively to fund a second procedure also thins the donor area itself, which becomes visible on short haircuts and constrains everything after.

So the second surgery is not simply an extra expense. It is capacity spent replacing hair you already had, rather than adding density where you wanted it. Patients who arrive on this treadmill are frequently in their thirties with two procedures behind them, a depleted donor area, and a pattern that is still advancing.

The medications do not add hair the way surgery does. What they do is far more valuable in this specific context: they slow the thing that makes the second and third procedures necessary.

Finasteride: what the long-term data says, and the conversation to actually have

Finasteride is a 5-alpha-reductase inhibitor. It blocks conversion of testosterone into dihydrotestosterone, the androgen that drives follicular miniaturisation in genetically susceptible scalps. It is oral, generic, and taken daily and indefinitely — stop it and the underlying process resumes.

The long-term data is unusually good for a cosmetic-adjacent drug. A cohort of Japanese men with androgenetic alopecia treated with finasteride and followed for five years evaluated 801 patients by modified global photographic assessment. The proportion showing improvement was very high, and the sustained effect over five continuous years is the headline.

But the finding that should determine your timeline is the multivariate one. Independent predictors of insufficient efficacy at five years were starting treatment at age 40 or older, and more advanced disease on the modified Norwood-Hamilton scale. Younger age and less advanced loss at initiation predicted a better result.

Read that alongside the transplant question and the sequencing answers itself. The drug works best when started early and at a less advanced stage — which is to say, before the loss has progressed to the point where someone is booking surgery, not after. Stabilising first is not a delay tactic imposed by cautious doctors. It is using the treatment during the window in which it performs best.

The side-effect conversation deserves to be had properly rather than in either direction of caricature. Sexual side effects — reduced libido, erectile difficulty, ejaculatory changes — are reported, at low rates above placebo in the registration trials, and they are generally reversible on stopping. There is a genuinely contested literature on whether a subset of men experience persistent symptoms after discontinuation, and mood effects have been reported. Anyone telling you the risk is zero is overselling, and anyone telling you it is common is overstating; the honest position is that the rates are low, the debate about persistence is unresolved, and it is a decision to make with a clinician who will discuss it rather than with a forum thread. Finasteride is also contraindicated in pregnancy and must not be handled by anyone who could become pregnant, because of teratogenic risk to a male fetus. Topical finasteride formulations exist and are used to reduce systemic exposure; the evidence base is younger and thinner than for oral, which is worth knowing before treating it as a free lunch.

Minoxidil, and the shed that makes people quit

Minoxidil works by a different route — a vasodilator whose hair effect appears to involve shortening telogen and prolonging anagen — and it is the other half of the medical foundation. It comes in two forms that are worth distinguishing.

Topical minoxidil is available over the counter in solution and foam, applied to the scalp daily. It is the option with the longest consumer track record, and its main failure mode is adherence: it is fiddly, it can irritate, and it has to be continued indefinitely.

Low-dose oral minoxidil is prescribed off-label and has become considerably more common in dermatology practice over the last several years. It removes the application problem, and it introduces systemic considerations — fluid retention, hypertrichosis in unwanted places, and cardiovascular questions that require a clinician's assessment rather than a website's. Recent work has looked at whether dosing time affects efficacy, which is an indication of how actively the protocol is still being refined.

The practical point that saves the most treatment courses concerns shedding. Starting minoxidil frequently produces a temporary increase in hair fall in the first weeks, as follicles are pushed synchronously out of telogen into a new growth cycle. It is alarming, it arrives exactly when someone has committed to a new treatment, and it is the single most common reason people stop. A retrospective cohort examining low-dose oral minoxidil found that temporary shedding at initiation does not preclude long-term benefit — which is the reassurance to have in hand before it happens rather than after you have already quit.

Both drugs are judged in months, not weeks. Six months is the earliest reasonable assessment point and twelve is better, because the hair cycle sets the pace and nothing you do accelerates it.

What a good surgeon does, and the question that reveals one

The sequencing an ethical practice follows is unglamorous and fairly consistent.

Diagnose first. Not all hair loss is androgenetic, and the alternatives matter enormously — thyroid dysfunction, iron deficiency, telogen effluvium following illness or major stress, traction from styling, and the scarring alopecias, which destroy follicles permanently and are an urgent medical problem rather than a surgical one. Transplanting into an undiagnosed scarring alopecia is a way of losing grafts as well as native hair.

Stage it. Where you sit on the standard scales predicts how far the pattern is likely to extend, which determines whether a hairline you want now will look plausible in twenty years. Our hair loss stages tool walks through those scales.

Stabilise medically, then wait. Six to twelve months on treatment tells the surgeon two things they cannot otherwise know: how your loss responds, and how fast it is moving. That information changes the surgical plan — how conservative the hairline should be, how much donor to reserve, whether to operate at all yet.

Photograph properly throughout. Standardised images at fixed distance, angle and lighting, at fixed intervals, are the only way to distinguish real change from a good day. Our photo tracker exists for this, and it is worth starting on day one rather than reconstructing later. The same discipline is what makes a clinic's own marketing images assessable — ↗our answer on judging before-and-after photos sets out what to look for, and inconsistent lighting between the two frames is the tell that recurs most often.

Then decide on surgery, with the medication continuing afterwards indefinitely.

The single question that sorts practices: what happens to my native hair over the next ten years if I have this surgery and take nothing? A surgeon who answers that directly — describing continued miniaturisation, the likely need for further procedures, and the donor cost of each — is someone reasoning about your decade. A consultation that moves to graft counts and financing without ever raising it has told you what it is optimising for. ↗Our answer on what to ask before a cosmetic procedure generalises the same test, and our derm visit prep tool will help you arrive with the list written down.

What skincare can and cannot do here

It is worth being precise about the limits of everything sold over a counter, because hair loss is a category where the gap between marketing and mechanism is unusually wide.

No shampoo, serum or scalp oil available without a prescription has evidence approaching finasteride or minoxidil for androgenetic alopecia. Not one. Products in this space are frequently sold with growth language they cannot support, and the caffeine, ↗rosemary and peptide claims that circulate rest on small studies, laboratory work, or nothing at all.

What scalp care genuinely does is manage the conditions that sit alongside hair loss, and those are worth managing on their own terms. Seborrhoeic dermatitis is common, itchy, and treatable: ↗ketoconazole has the best evidence among antifungal actives, and Nizoral Anti-Dandruff Shampoo is the straightforward way to deliver it. Build-up from styling products and sebum responds to a ↗salicylic acid treatment such as The INKEY List Salicylic Acid Exfoliating Scalp Treatment. A scalp irritated by daily minoxidil application — a common and under-discussed reason people abandon it — is often rescued by a soothing leave-on like Jupiter Restoring Serum or a pre-wash treatment such as Briogeo Scalp Revival Rosemary Pre-Wash Oil, which is a genuinely useful role even though the botanical itself is not the reason.

That last case is the honest summary of the whole category. Good scalp care does not grow hair. It removes the reasons people stop doing the things that do — and given that both first-line treatments only work while you keep taking them, adherence is not a minor variable. It is most of the outcome.

If you take one thing from this: the order matters more than any individual choice within it. Diagnose, stage, stabilise, photograph, wait, then operate — and keep taking the medication afterwards. A transplant is a redistribution of a finite resource, and it is worth doing once, well, into a field that has stopped moving.